Novo Nordisk has just made history: its blockbuster Wegovy drug is now the first GLP-1 therapy approved for liver disease (MASH) in the U.S. — unlocking a multi-billion-dollar market opportunity beyond weight loss and diabetes. With shares already up 5% on the news, investors are asking: Is this the start of Novo’s next rally toward $200+?
At BullishStockAlerts.com, we break down the targets across short, mid, and long-term timeframes, giving you the edge before Wall Street catches on. Don’t miss your chance to ride the momentum of this game-changing approval — the next big biotech winner could already be on our radar.
👉 Act now and get exclusive insights at BullishStockAlerts.com.






